SG Americas Securities LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

SG Americas Securities LLC bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 13,483 shares of the company’s stock, valued at approximately $244,000.

A number of other large investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Phathom Pharmaceuticals by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock worth $104,000 after purchasing an additional 2,987 shares during the last quarter. Klingman & Associates LLC bought a new stake in shares of Phathom Pharmaceuticals in the 1st quarter worth approximately $110,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Phathom Pharmaceuticals in the 1st quarter worth approximately $119,000. LVW Advisors LLC bought a new stake in shares of Phathom Pharmaceuticals in the 2nd quarter worth approximately $133,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Phathom Pharmaceuticals by 10.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after purchasing an additional 1,339 shares during the last quarter. Institutional investors own 99.01% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on PHAT shares. Needham & Company LLC reissued a “buy” rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, September 13th. The Goldman Sachs Group raised their price target on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Monday, August 12th.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT stock opened at $15.52 on Tuesday. Phathom Pharmaceuticals, Inc. has a 1 year low of $6.07 and a 1 year high of $19.71. The stock has a market cap of $908.46 million, a PE ratio of -3.52 and a beta of 0.71. The business’s fifty day moving average is $16.30 and its 200-day moving average is $12.64.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its earnings results on Thursday, August 8th. The company reported ($1.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.39) by $0.04. The company had revenue of $7.32 million during the quarter, compared to analyst estimates of $5.65 million. Equities research analysts predict that Phathom Pharmaceuticals, Inc. will post -6.03 earnings per share for the current year.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.